Pediatric Hematology/Oncology

Cardiology

Questions discussed in this category

At what cumulative anthracycline dose is it recommended to use dexrazoxane for cardioprotection?

2 Answers available

How is your experience with point-of-care INR systems for home monitoring of vitamin K antagonists?

Are the INRs reliable? In what scenarios would you not recommend POC INR use for warfarin monitoring? Are these typically covered by insurance? Are t...

1 Answer available

Should all patients with a remote history of immunotherapy, chemotherapy and/or radiation therapy have a baseline TTE regardless of ASCVD risk?

2 Answers available

How do you manage patients blood pressures while on anti-angiogenic TKIs?

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

1 Answer available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Can CAR T cell therapy be considered for heart transplant recipients with concurrent lymphoproliferative disorders?

1 Answer available

For patients on immune checkpoint inhibitors presenting with chest pain, dyspnea, fatigue, and troponin elevation, would you recommend early initiation of high dose steroids for empiric treatment of ICI myocarditis while pursuing workup with coronary angiogram, echocardiogram, and/or cardiac MRI, or wait until alternative etiologies have been ruled out?

2 Answers available

What is your surveillance approach for outpatient monitoring of ICI myocarditis?

(i.e. frequency of serial BNP, troponin, cMRI)

2 Answers available

Given recent studies investigating ICI myocarditis biomarkers such as Temra CD8+ cells, is there now a growing selection of clinical biomarkers, besides BNP and troponin, being measured routinely in ICI myocarditis cases?

2 Answers available

When would you consider tapering glucocorticoids in a patient with ICI-associated myocarditis?

2 Answers available

Would you give doxorubicin and cisplatin for localized chondroblastic osteosarcoma in a patient with prior childhood anthracycline exposure and resultant cardiomyopathy with EF 50%?

3 Answers available

What precautions do you take prior to CABG in a patient with sickle cell trait?

Please comment on temperature recommendations and role of exchange transfusion.

1 Answer available

Would you consider using DOACs in a young patient with SLE and Libman-Sacks endocarditis, who is negative for APS?

2 Answers available

Is dexrazoxane recommended for cardioprotection in AYA patients with Hodgkin lymphoma who are receiving anthracyclines as part of their upfront therapy?

3 Answers available

Papers discussed in this category

The Cochrane database of systematic reviews, 2011 Jun 15

Cardioprotective interventions for cancer patients receiving anthracyclines.

JACC. CardioOncology, 2019 Sep 24

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer.

JAMA, 2023 Aug 8

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.

JACC. CardioOncology, 2024 Apr 16

Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: : CardioOncology Controversies in Cardio-Oncology.

JACC. CardioOncology, 2023 May 02

The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer.

Heart failure reviews, 2025 Feb 17

The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

J Clin Oncol, 2020 Apr 28

Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Blood, 2009-09-03

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

Eur Heart J, 2022 Nov 01

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

JACC CardioOncol, 2022 Dec 20

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.

The American journal of cardiology, 2018-12-01

Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.

Curr Oncol, 2021 Oct 13

Exercise to Reduce Anthracycline-Mediated Cardiovascular Complications in Breast Cancer Survivors.

Cardiooncology, 2019 Jan 29

Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series.

Pediatr Transplant, 2021 Aug

Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.

Br J Haematol, 2023 May 2

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.

Bone marrow transplantation, 2022 Dec 27

CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.

Eur Heart J, 2022 Jan 31

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

J Am Heart Assoc, 2020 Jan 21

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.

Circulation, 2020 Jun 15

Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.

Related Topics in Pediatric Hematology/Oncology